Tricyclic compounds as BCR-ABL inhibitors
US11987575B2 · kind B2 · utility
0Cited by
1References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 29, 2020 |
| Grant date | May 21, 2024 |
| Priority date | — |
| Expiry date | May 18, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure provides compounds represented by Formula I, or an enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, L, Ar, R1, R2, R3 R4, R5, R6, m, and p are defined herein. Compounds of Formula I are BCR-ABL inhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.